Rivervest
QuietSt. Louis, MOPharmaceuticals, Healthcare, BiotechnologyLast fund filed October 2020
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| RiverVest Venture Fund V | October 2020 | $275M | $275M | 96 |
| RiverVest Venture Fund IV | December 2017 | $168M | $168M | 68 |
| RiverVest Venture Fund III (Ohio) | March 2015 | $4M | $4M | 2 |
| RiverVest Venture Fund III | March 2014 | $150M | $79M | 48 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Jay Schmelter | Quiet | Medical devices, Digital health | 7 | 0 |
Classified sectors of Rivervest’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Rivervest’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| NEA | 6 | Allakos, Amplyx Pharmaceuticals, Curzion Pharmaceuticals, Lumena Pharmaceuticals, Mirum Pharmaceuticals, Reneo Pharmaceuticals |
| Camber Creek | 2 | Alleviant Medical, InterVene |
| Grayhawk | 2 | Alleviant Medical, VentureMed Group |
| ARCH Venture Partners |
| John McKearn | Quiet | Biotech & pharma | 9 | 0 |
| Karen SpilizewskiNot on the current fund | Quiet | None listed | 1 | 0 |
| Niall O'Donnell | Quiet | Biotech & pharma | 9 | 0 |
| Thomas MelzerNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| OncoResponse |
| Greatpoint Ventures Innovation | 1 | OncoResponse |
| Orbimed Asia Partners | 1 | Sparrow Pharmaceuticals |
| Orbimed Genesis | 1 | Sparrow Pharmaceuticals |
| Sofinnova Venture Partners | 1 | Amplyx Pharmaceuticals |
| U.S Venture Partners | 1 | Sparrow Pharmaceuticals |
| Versant Venture Capital | 1 | Alleviant Medical |
| Vivo Innovation | 1 | Bonum Therapeutics |
A shared board seat: a company where filings name a Rivervest partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.